SAN
SANOFI
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Sanofi is the result of the merger of several French laboratories, including Synthélabo, Aventis – which emerged from the combination of Rhône-Poulenc and Hoechst – and the pharmaceutical activities of Sanofi-Synthélabo. The group is a global player in health and biotechnology, active in rare diseases, vaccines, and consumer healthcare. It has distinguished itself through major advancements such as glargine insulin (Lantus), a reference treatment for diabetes, and iconic vaccines against poliomyelitis, rabies, and influenza developed by Sanofi Pasteur. Sanofi invests in biotechnology research and the global production of vaccines, contributing to prevention and international health security.
SANOFI
SAN
Sanofi is the result of the merger of several French laboratories, including Synthélabo, Aventis – which emerged from the combination of Rhône-Poulenc and Hoechst – and the pharmaceutical activities of Sanofi-Synthélabo. The group is a global player in health and biotechnology, active in rare diseases, vaccines, and consumer healthcare. It has distinguished itself through major advancements such as glargine insulin (Lantus), a reference treatment for diabetes, and iconic vaccines against poliomyelitis, rabies, and influenza developed by Sanofi Pasteur. Sanofi invests in biotechnology research and the global production of vaccines, contributing to prevention and international health security.
Anantys Community
Anantys Community
4 members hold SANOFI with an average return of -6.1%. Join them to follow signals and build your long-term investment strategy.
Price history of SANOFI
Price history of SANOFI
Performance & Momentum
Sanofi faces Dupixent patent expiry in 2031
The article highlights growing concern among Sanofi executives as 2031 approaches, the year the patent protecting the flagship drug Dupixent will expire. This milestone could weaken the group's growth prospects, especially since current R&D investments are not leading to significant new drivers. The stock remains stable in the short term, reflecting cautious market anticipation.
Strategic Analysis
SANOFI • 2026
Sanofi has a strong positioning in vaccines and rare diseases combined with a targeted growth strategy through biotechnology innovation and acquisitions aimed at strengthening its portfolio. The group is focusing on flagship products like Dupixent to support its profitability in the medium term while anticipating the impact of patent expirations.
Strengths
- A wide range of vaccines and recognized expertise in global public health
- Leading innovative products in their markets, particularly Dupixent in inflammatory diseases
- Proactive external growth strategy with the acquisition of Dynavax strengthening its pipeline
Weaknesses
- Significant risk associated with the patent expiration of Dupixent in 2031
- Stock performance down over the past twelve months
Momentum
The current momentum of Sanofi reflects a challenging period despite an improvement in profitability for its flagship products. The recent integration of Dynavax demonstrates a strategic drive to offset upcoming pressures, but the stock trend indicates investor caution regarding medium-term issues related to patents and competition.
Similar stocks to SANOFI
Often held with SANOFI
Recent News
SANOFI
Sanofi Completes Acquisition of Dynavax
1 month agoOn February 10, 2026, Sanofi announced the completion of its acquisition of Dynavax Technologies, strengthening its portfolio in vaccines and immunotherapies. This move could boost the group's medium-term prospects, although the market reaction remains neutral despite a recent 4.19% dip, likely due to profit-taking or post-announcement volatility.
Sanofi Boosts Profitability with Dupixent Despite Stock Drop
2 months agoDespite a significant 24% decline over the past year, Sanofi surprised positively by reporting results that exceeded expectations and outlook generally in line with forecasts. This performance is notably driven by its flagship drug Dupixent, which continues to support the group's profitability. The recent 2.75% rally in the share price appears to reflect a moderate profit-taking by investors encouraged by these relatively strong financial results.
GTCR Acquires Zentiva for $4.8 Billion
6 months agoPrivate equity firm GTCR has completed its $4.8 billion acquisition of Zentiva, marking a significant move in the pharmaceutical sector. Although the deal does not directly involve Sanofi, Zentiva's role in the generic drug market could intensify competition within the industry. Sanofi's shares rose moderately by 1.43%, reflecting cautious market sentiment regarding potential indirect impacts of this acquisition.
Sanofi reports mixed Phase III results for amlitelimab
7 months agoOn September 4, 2025, Sanofi announced that its drug amlitelimab met the primary endpoints in a Phase III study for atopic dermatitis. However, the market reacted negatively due to the perceived modest performance. This partly explains the significant 7.92% drop in the stock, reflecting investor caution regarding clinical efficacy. Given the circumstances, a short-term 'sell' stance appears justified.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
